European Sovereignty: Health and Food, the New Front Lines
12 today 10:33
The Covid-19 pandemic exposed a vulnerability Europe had preferred to ignore: its structural dependence on external suppliers for essential medicines, medical equipment, and agricultural inputs. Since then, geopolitical tensions have only reinforced this assessment. The concentration of active pharmaceutical ingredient production in Asia, the fragility of supplies of antibiotics, insulin, and painkillers: these are now visible fault lines that demand a concrete response.
That response is taking shape. The EU Council and European Parliament have just reached an agreement on the Critical Medicines Act, a text aimed at reducing shortages of key medicines and relocating pharmaceutical production to European soil. This initiative is directly in line with the logic of the Draghi Report.
The text introduces three operational levers: mandatory resilience criteria in public procurement, with a preference for European suppliers; facilitated joint purchasing; and a contingency stock-sharing mechanism between member states. These three mechanisms feed directly into the "Secure Healthcare & Food" pillar of our "European Sovereignty" strategy, structured around three axes:
- Pharma: relocating the production of generics and active ingredients, accelerating manufacturing capacity in Europe, strengthening strategic stockpiles.
- Medtechs & other equipment: growth of European players in high-tech medical devices, driven by public procurement policies favouring local suppliers.
- Sustainable food: reducing dependence on imported inputs, developing resilient agricultural systems in a context of increasing climate disruption.
Our conviction on this theme remains unwavering. Geopolitical pressures, post-Covid healthcare resilience requirements, and the political will displayed in Brussels make this one of the most solid themes of the current cycle. Kepler Cheuvreux's research teams have identified, within each sub-theme, the companies best positioned to benefit.
Feel free to contact Renalco SA to learn more if you are interested in this opportunity (info@renalco.ch).
This article is produced by Renalco, in cooperation with Kepler Cheuvreux Solutions.
You may share the link to this article freely, whether through social media, email, or other means. However, you may not copy, reproduce, or republish any part of this article in any form or by any means without prior written permission from Renalco SA.
For inquiries regarding the use or licensing of this article, please contact info@renalco.ch.
Kepler Cheuvreux is an investment firm authorized by the ACPR under number 14441 and regulated by the Autorité des Marchés Financiers, incorporated in France under number RCS 413 064 841 at the following address: 112 Avenue Kleber, 75116 Paris, France (www.keplercheuvreux.com).
This document does not constitute a prospectus/regulatory document or other offering document, nor does it constitute an offer or solicitation to purchase securities or other investments. It should not be construed as an offer to sell or a proposal to buy any securities in any jurisdiction in which such an offer or proposal would be unlawful. We are not soliciting any action on the basis of this document, which is provided to our clients for general information purposes. It does not constitute an investment recommendation or a personalized recommendation, and does not take into account the investment objectives, financial situation and needs of each client. Before acting on the contents of this document, we advise you to check whether it is suitable for your particular situation and, if necessary, to seek professional advice.
The figures relating to past performances refer or relate to past periods and are not a reliable indicator of future results.
The accuracy, completeness or timeliness of information from external sources is not guaranteed, although it was obtained from sources reasonably believed to be reliable. Kepler Cheuvreux assumes no responsibility in this regard.
Information provided in this document concerning market data is retrieved from databases at a precise period of time and is subject to variations.
